You are here

  • Home
  • Archive
  • Volume 5, Issue Suppl 1
  • S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study

Article metrics

Article menu

Download PDFPDF

S7a – New therapeutic candidates
S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study
Free

 

Online download statistics by month:

Online download statistics by month: March 2018 to September 2024

AbstractFullPdf
Mar 20183606
Apr 20183406
May 201838013
Jun 201828014
Jul 201859020
Aug 201860010
Sep 201888016
Oct 2018168036
Nov 201874016
Dec 20184206
Jan 20197209
Feb 20192706
Mar 201942010
Apr 201950012
May 20193207
Jun 20192102
Jul 20194305
Aug 20194107
Sep 201937011
Oct 201957019
Nov 20192303
Dec 201970016
Jan 20204805
Feb 20201908
Mar 20201304
Apr 20201600
May 202027011
Jun 20201803
Jul 20205102
Aug 20201401
Sep 20203303
Oct 20207108
Nov 2020901
Dec 20201503
Jan 20211404
Feb 20211204
Mar 2021802
Apr 2021602
May 2021506
Jun 2021003
Jul 2021102
Aug 2021306
Sep 2021508
Oct 202122017
Nov 202115018
Dec 2021704
Jan 20221709
Feb 2022504
Mar 20222000
Apr 2022801
May 2022809
Jun 2022804
Jul 20221901
Aug 20221104
Sep 2022509
Oct 20221405
Nov 202219017
Dec 20221200
Jan 2023902
Feb 20231103
Mar 20231105
Apr 20235014
May 2023706
Jun 20232204
Jul 2023602
Aug 2023403
Sep 2023502
Oct 20231606
Nov 20231901
Dec 2023901
Jan 2024601
Feb 20242400
Mar 20242004
Apr 20242202
May 20241002
Jun 20242606
Jul 20242205
Aug 20241702
Sep 20241303
Total20040512